NOV 01, 2015 08:25 AM PST

Towards Precision Medicine for Prostate Cancer with Olaparib

WRITTEN BY: Xuan Pham

Gene-targeted and personalized therapy currently exists for a small handful of diseases, but that list may soon include prostate cancer.
 

Image credit: Pixabay.com


Prostate cancer represents a huge health risk for half the world’s population, as it is the most common form of cancer in men. Current treatments for the disease are confined to the affected prostate tissue, commonly involving radiation and chemotherapy aimed at the cancer cells in the prostate, or surgical removal of the prostate itself. But the line of defense against prostate cancer may have strengthened dramatically with olaparib, a drug that specifically targets DNA-repair genes.
 
Olaparib is not a novel drug. Manufactured by Astrazeneca under the tradename Lynparza, olaparib was recently approved by the FDA as a cancer drug for ovarian cancers associated with BRCA1/2 mutations. In these types of cancers, there’s a propensity of the cancer cells to rely only on the enzyme poly ADP-ribose polymerase (PARP) to repair its constantly dividing DNA. The drug olaparib exploits this vulnerability and acts as a PARP inhibitor, effectively killing the cancer cells by allowing DNA damages to go unrepaired, while having no adverse effects on normal cells.
 
BRCA1/2 mutations are also the cause of some prostate cancers. In a recent study by the Institute of Cancer Research in London, olaparib was given to a cohort of 49 men with treatment-resistant and metastatic prostate cancer. Within this cohort, 16 men showed tumor mutations in DNA damage-repair genes, including BRCA1/2, ATM, PALB2, CHEK2, FANCA, and HDAC2. The team reported significantly higher response rate to olaparib for these 16 men out of the group of 49, citing greater than 50% reduction in prostate specific antigen (PSA) levels, decreased prostate cancer cells, and shrinkage of secondary tumors.

"This trial is exciting because it could offer a new way to treat prostate cancer by targeting genetic mistakes in cancers that have spread," said Dr Áine McCarthy of the UK Cancer Research.

Beyond the immediate positive response of the trial, the real excitement for the research team rests in the identification of the mutations in DNA-repair genes from the 16 men with the best response to olaparib. Notably these genes have all shown lethal adverse interactions with PARP inhibitors, representing a promising avenue for precision medicine in the treatment of prostate cancer.
 
Though hopeful of combining genetic analysis and targeted drug therapy for prostate cancers, Dr. Emma Hall, study co-leader of the ICR, stressed follow-up trials. With the results of this clinical study, the next steps will be to demonstrate the specificity and efficacy of olaparib on the subset of prostate cancers caused by DNA-repair mutations.

 “The next trial includes only men with these mutations in their tumors, with the aim of proving that olaparib is highly effective for them," said Dr. Emma Hall.

Knowing the genetic mutations associated with each prostate cancer could redefine the clinical diagnosis and subsequent therapy for each patient. Those who exhibit tumor mutations in the DNA repair genes could be treated with PARP inhibitors as a first line of defense. Because the treatment is tailored to the patient’s genetic profile, the hope is that many more lives will be saved in the future.
 
Through active surveillance and screening, the mortality rate for prostate cancer has dramatically been reduced. However, prostate cancer remains one of the top leading causes of cancer-related deaths for men worldwide. The current study represents a huge achievement for prostate cancer treatment, identifying olaparib as a highly targeted prostate cancer drug. The study has also added to the groundwork for future clinical therapy that’s based on individual genetic profiles.

Watch the video to learn more about how PARP inhibitors like olaparib work!


Source: NEJM

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 16, 2019
Cardiology
OCT 16, 2019
How Is Cardiovascular Rehabilitation Failing Woman
For woman across North America, cardiovascular disease (CVD) remains a leading cause of death. Evidence strongly suggests that CVD risk factors such as poo...
OCT 16, 2019
Health & Medicine
OCT 16, 2019
Pulmonary Hypertension in Sarcoidosis
Sarcoidosis is an inflammatory disease that involves the formation of non-caseating granulomas, a cluster of macrophages, in response to a foreign sub...
OCT 16, 2019
Cardiology
OCT 16, 2019
Beyond Annoying, Noise Is Bad For Your Health
Peace and quiet are hard to come by these days. Cities are rife with noise pollution from a significant number of sources. Everything from automotive traff...
OCT 16, 2019
Health & Medicine
OCT 16, 2019
Can Scientists Create a Blood Test to Screen for Alzheimer's Risk?
Currently, to gauge the risk of Alzheimer’s disease, patients must undergo brain scans, spinal fluid tests, or mental assessments; all of which can b...
OCT 16, 2019
Clinical & Molecular DX
OCT 16, 2019
A Blood Drop Test for Rapid Detection of Traumatic Brain Injury
A study published by Yue et al., in August 2019, reported that a simple blood test (a few drops of blood) can detect traumatic brain injury efficiently and...
OCT 16, 2019
Chemistry & Physics
OCT 16, 2019
What is Photoacoustic Imaging?
In the last decade, photoacoustic tomography has slowly emerged as a versatile, radiation-free imaging modality that bears great potentials for basic resea...
Loading Comments...